Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer
- PMID: 30360816
- DOI: 10.1016/bs.enz.2018.08.004
Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer
Abstract
Breast and ovarian cancer are the leading cause of cancer-related deaths in women in the United States with over 232,000 new Breast Cancer (BC) diagnoses expected in 2018 and almost 40,000 deaths and an estimated 239,000 new ovarian cancer (OC) cases and 152,000 deaths worldwide annually. OC is the most lethal gynecologic malignancy. This high mortality rate is due to tumor recurrence and metastasis, primarily caused by chemoresistant cancer stem-like cells (CSCs). Triple Negative Breast Cancer (TNBC) patients also become resistant to chemotherapy due to recurrence of CSCs. Currently, no ovarian or breast cancer therapies target CSC specifically. TWIST is overexpressed in the majority of chemoresistant cancers resulting in a low survival rate. Our long-term goal is to develop novel treatments for women with ovarian and breast cancer, specifically treatments that sensitize chemoresistant tumors. Despite successful initial surgery and chemotherapy, over 70% of advanced EOC will recur, and only 15-30% of recurrent disease will respond to chemotherapy (Cortez et al., 2017; Berezhnaya, 2010; Jackson et al., 2015). Moreover, drug resistance causes treatment failure in over 90% of patients with metastatic disease (Solmaz et al., 2015). Thus, recurrent metastatic disease is a major clinical challenge without effective therapy. One of the major challenges in the treatment of breast cancer is the presence of a subpopulation of cancer cells that are chemoresistant (CRC) and metastatic. Given that metastasis is the driving force behind mortality for breast and ovarian cancer patients, it is essential to identify the characteristics of these aberrant cancer cells that allow them to spread to distant sites in the body and develop into metastatic tumors. Understanding the metastatic mechanisms driving cancer cell dispersal will open the door to developing novel therapies that prevent metastasis and improve long-term outcomes for patients. In this chapter we assess the feasibility of targeting the Twist and EMT signaling pathways in breast and ovarian cancer. Additional discussions of the pathways that mediate epithelial-mesenchymal transition (EMT), a process that can give rise to chemoresistance. We review potential treatment strategies for targeting EMT and drug resistance as well as the problems that may arise with these targeted delivery therapeutic approaches. Finally, we examine recent advances in the field, including cancer stem cell targeted nanoparticle delivery and small interference RNA (siRNA) technology, and discuss the impact that these approaches may have on translating much needed therapeutic approaches into the clinic, for the benefit of patients battling this devastating disease.
Keywords: Epithelial to mesenchymal transition; Hyaluronic acid; Mesoporous silica nanoparticles; Polyamidoamine dendrimers; Small interfering RNAs; TWIST, basic helix-loop-helix transcription factor.
© 2018 Elsevier Inc. All rights reserved.
Similar articles
-
Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer.Mol Cancer Ther. 2019 Feb;18(2):437-447. doi: 10.1158/1535-7163.MCT-18-0584. Epub 2018 Nov 6. Mol Cancer Ther. 2019. PMID: 30401696
-
Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models.Nanomedicine. 2017 Apr;13(3):965-976. doi: 10.1016/j.nano.2016.11.010. Epub 2016 Nov 25. Nanomedicine. 2017. PMID: 27890656 Free PMC article.
-
Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.Oncotarget. 2016 Aug 23;7(34):55771-55788. doi: 10.18632/oncotarget.9908. Oncotarget. 2016. PMID: 27304054 Free PMC article. Review.
-
RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis.Biomed Res Int. 2015;2015:382745. doi: 10.1155/2015/382745. Epub 2015 Feb 11. Biomed Res Int. 2015. PMID: 25759817 Free PMC article.
-
Targeting the Twist and Wnt signaling pathways in metastatic breast cancer.Maturitas. 2014 Sep;79(1):48-51. doi: 10.1016/j.maturitas.2014.06.015. Epub 2014 Jul 18. Maturitas. 2014. PMID: 25086726 Review.
Cited by
-
The Proteolytic Landscape of Ovarian Cancer: Applications in Nanomedicine.Int J Mol Sci. 2022 Sep 1;23(17):9981. doi: 10.3390/ijms23179981. Int J Mol Sci. 2022. PMID: 36077371 Free PMC article. Review.
-
The interferon regulatory factor 6 promotes cisplatin sensitivity in colorectal cancer.Bioengineered. 2022 Apr;13(4):10504-10517. doi: 10.1080/21655979.2022.2062103. Bioengineered. 2022. PMID: 35443865 Free PMC article.
-
TWIST1 expression is associated with high-risk neuroblastoma and promotes primary and metastatic tumor growth.Commun Biol. 2022 Jan 12;5(1):42. doi: 10.1038/s42003-021-02958-6. Commun Biol. 2022. PMID: 35022561 Free PMC article.
-
Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements.Pharmaceutics. 2020 Sep 29;12(10):929. doi: 10.3390/pharmaceutics12100929. Pharmaceutics. 2020. PMID: 33003468 Free PMC article. Review.
-
Elucidating the molecular signaling pathways of WAVE3.Ann Transl Med. 2020 Jul;8(14):900. doi: 10.21037/atm.2020.02.16. Ann Transl Med. 2020. PMID: 32793744 Free PMC article. Review.